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1. Introduction 
The functional foods concept started in Japan in the early 1980s with the launch of three 
large-scale government-funded research programs on systematic analyses and development of 
functional foods, analyses of physiological regulation of the functional food and analyses of functional 
foods and molecular design (Ashwell 2002; Pravst et al. 2010). In 1991, in an effort to reduce the 
escalating cost of health care, a category of foods with potential benefits was established 
(Foods for Specified Health Use – FOSHU) (Ashwell 2002). In the USA, evidence-based 
health or disease prevention claims have been allowed since 1990, when the Nutrition 
Labelling and Education Act was adopted; claims have to be approved by the Food and Drug 
Administration (FDA) (Arvanitoyannis and Houwelingen-Koukaliaroglou 2005). Codex 
Alimentarius Guidelines for the use of nutrition and health claims were accepted in 2004, and 
amended in 2008 and 2009, followed by Recommendations on the scientific basis of health claims 
(Grossklaus 2009). In the European Union, harmonisation was achieved in 2006 with 
Regulation (EC) No 1924/2006 on nutrition and health claims made on foods, which requires 
authorization of all health claims before entering the market. 
The definition of functional foods is an ongoing issue and many variations have been 
suggested (Arvanitoyannis and Houwelingen-Koukaliaroglou 2005). A consensus on the 
functional foods concept was reached in the European Union in 1999, when a working 
definition was established whereby a food can be regarded as functional if it is satisfactorily 
demonstrated to beneficially affect one or more target functions in the body beyond 
adequate nutritional effects in a way that is relevant to either an improved state of health 
and well-being or a reduction of disease risk. Functional foods must remain foods and 
demonstrate their effects when consumed in daily amounts that can be normally expected 
(Ashwell 2002). In practice, a functional food can be: an unmodified natural food; a food in 
which a component has been enhanced through special growing conditions, breeding or 
biotechnological means; a food to which a component has been added to provide benefits; a 
food from which a component has been removed by technological or biotechnological 
means so that the food provides benefits not otherwise available; a food in which a 
component has been replaced by an alternative component with favourable properties; a 
food in which a component has been modified by enzymatic, chemical or technological 
means to provide a benefit; a food in which the bioavailability of a component has been 
modified; or a combination of any of the above (Ashwell 2002). Regardless of the various 
definitions, the main purpose of functional food should be clear – to improve human health 
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and well-being. However, health claims are a very convenient tool when it comes to 
marketing functional foods. The latest analyses show that in some European countries 
health claims are now used in over 15% of commonly eaten packaged foods (Lalor et al. 
2010). Consumers are very sensitive to health-related communications and the use of health 
claims is unfortunately often connected with intentions to mislead them (Pravst 2011b). 
While this is clearly prohibited by law (Colombo 2010), companies are employing 
innovative strategies to avoid these rules so as to make a greater profit. Sophisticated 
regulation of this area is needed to provide consumers with high quality foods and non-
misleading information. In this review the assessment of functional foods and their use in 
Europe will be critically discussed. 
2. Consumer acceptance of functional foods and nutrition labelling 
Health-related information on food labels may play a crucial role in informing consumers 
and influence their purchase decisions (Pothoulaki and Chryssochoidis 2009). However, 
consumer acceptance is far from unconditional and depends on beliefs about functional 
foods being viewed as a marketing stunt, as well as on familiarity and perceptions related to 
the perceived fit of ingredients and carrier or base products rather than on classical 
demographic characteristics (Verbeke 2010). In addition, it is unlikely one can count on 
consumer willingness to compromise on the taste of functional foods for health (Verbeke 
2006). Recent studies show that the consumer might have a stronger preference for simple 
health statements compared to the implied benefits that result from consuming a functional 
food product (Bitzios et al. 2011). Indeed, consumers’ attitudes to functional foods and the 
use of nutrition information or claims on food labels have been studied extensively in recent 
years (Bitzios et al. 2011; Hoefkens et al. 2011; Krutulyte et al. 2011; Pothoulaki and 
Chryssochoidis 2009; Urala and Lahteenmaki 2004; Verbeke 2005; Verbeke 2006; Verbeke et 
al. 2009) and some useful reviews of these topics are available (Bech-Larsen and Scholderer 
2007; Pothoulaki and Chryssochoidis 2009; Verbeke 2010; Wills et al. 2009). 
A recent multi-country study confirmed that consumers perceive some nutrients as 
qualifying (fibre, vitamins and minerals) or disqualifying (energy, fat, saturated fat, salt, 
sugars) (Hoefkens et al. 2011) and only small differences are observed between countries. 
Overall, consumers perceive the nutritional value of foods as important when selecting 
foods, particularly when it comes to qualifying nutrients (Hoefkens et al. 2011). Such a 
finding is quite interesting since public health nutrition awareness campaigns across Europe 
mainly target disqualifying nutrients, i.e. salt (Celemin et al. 2011). The marketing 
campaigns of the food industry can obviously have very strong effects, particularly if 
consumers perceive them as trustworthy. It must be noted that the labelling of nutrition 
information on foods in the EU is currently not mandatory, except for foods with nutrition 
and health claims. This is about to change under the accepted Regulation on the provision of 
food information to consumers. However, most food labels already contain at least back-of-
pack nutrition labelling or related information, although there are significant differences 
between various food categories and countries (Bonsmann et al. 2010). 
3. Assessment of functionality 
The effects of particular functional foods on human health must be based on scientific 
evidence of the highest possible standard. However, because a direct measurement of the 
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effect a food has on health is not always possible, the key issue is to identify critical 
biomarkers that can be used to monitor how biological processes are being influenced 
(Howlett 2008). If appropriate biomarkers are chosen it is possible to study the effect of the 
food on the final endpoints by measuring the biomarkers. The markers could be chosen to 
reflect either some key biological function or a key stage in development that is clearly 
linked to the study endpoint (markers of an intermediate endpoint) (Fig. 1) (Howlett 2008). 
In such a way we can study the long-term effects in the shorter term. Nonetheless, the 
biomarkers must be very carefully selected. 
 
 
Fig. 1. The use of markers to link food consumption to health outcomes. Reproduced with 
permission of ILSI Europe (Howlett 2008). 
In Europe the consensus on the criteria for the scientific support for claims on foods was 
reached in 2005 within PASSCLAIM – the Process for the Assessment of Scientific Support 
for Claims on Foods (Aggett et al. 2005). It delivered criteria to assess the scientific support 
for claims on foods. The set of criteria developed were derived through an iterative 
continuous improvement process that involved developing and evaluating criteria against 
key health claim areas of importance in Europe. These areas included diet-related 
cardiovascular disease, bone health, physical performance and fitness, body-weight 
regulation, insulin sensitivity and diabetes risk, diet-related cancer, mental state and 
performance and gut health and immunity. Expert groups reviewed the availability of 
indicators of health and disease states within their respective areas of expertise. They have 
demonstrated the limitations of existing biomarkers and have identified the need for better 
biomarkers (Aggett et al. 2005). 
3.1 Food vs. medicine 
In a time when the role of a healthy diet in preventing non-communicable diseases is well 
accepted, the borderline between foods and medicine is becoming very thin. The concept of 
foods should obviously go beyond providing basic nutritional needs. While products intended 
to cure diseases are classified as medicine, a healthy diet consisting of foods with functional 
properties can help promote well-being and even reduce the risk of developing certain 
diseases (Howlett 2008). However, a diet can only be healthy if the combination of individual 
foods is good. Limiting certain components (e.g. salt and saturated or trans fatty acids) or 
simply delivering an intake of nutrients cannot be regarded as a healthy diet. While it is easy 
to give advice on a healthy diet, it is much harder to define it for a particular need.  
The borderline between food and medicine is shown in Table 1. As with traditional foods, 
functional foods should also not have serious side effects when consumed in reasonable 
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amounts, although some functional foods can be intended for specific populations. This is 
contrary to medicine, which is intended for curing a disease or treating its symptoms, and 
used in exactly defined quantities to minimize side effects and assure therapeutic action. 
Food legislation also defines food supplements and foods for special medical purposes. Food 
supplements are concentrated sources of nutrients or other substances with a nutritional or 
physiological effect and are meant for supplementing a normal diet. Supplements are 
usually marketed as capsules, pastilles, tablets, pills and other similar forms of liquids and 
powders designed to be taken in measured small unit quantities. In contrast, foods for special 
medical purposes are specifically formulated, processed and intended for the dietary 
management of diseases, disorders or medical conditions of individuals who are being 
treated under medical supervision. These foods are intended for the exclusive or partial 
feeding of people whose nutritional requirements cannot be met by normal foods.  
 
 Functional food Medicinal food Medicine 
Usage Providing nutritional 
needs, weight 
management, supporting 
health of digestive system, 
skeleton, heart, reducing 
risk of development of 
certain diseases. 
Food management of 
some diseases or certain 
medical conditions, in 
which there are specific 
nutritional needs (i.e. 
problems with 
swallowing, lost appetite, 
postoperative nutrition) 
Curing disease 
or treating its 
symptoms 
To be consumed: As wanted As needed As prescribed 
Table 1. The borderline between food and medicine (Raspor 2011) 
4. Functional foods in the context of regulation 
To promote the use of any particular functional food its beneficial effects must be 
communicated to consumer. This is usually done through the use of nutrition and health 
claims in the labelling and advertising of foods. In this context, functional foods in Europe 
are probably most critically affected by the Regulation (EC) No 1924/2006 on nutrition and 
health claims made on foods (EC 2006). The regulation applies to all nutrition and health claims 
made in commercial communications, including trademarks and other brand names which 
could be construed as nutrition or health claims. The general principle is that claims should 
be substantiated by generally accepted scientific data, non-misleading and pre-approved on 
the EU level. Additionally, claims shall not give rise to doubt about the safety of other foods 
or encourage excessive consumption of a food. 
4.1 Nutrition claims 
The regulation defines a nutrition claim as any claim stating, suggesting or implying that a 
food has particular beneficial nutritional properties due to the calorific value or composition 
with respect to the presence (or absence) of specific nutrients or other substances. Only 
nutrition claims which are listed in the regulation are allowed, providing they are in 
accordance with the set conditions of use. Some examples of authorised nutrition claims and 
the conditions applying to them are listed in Table 2.  
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Nutrition claim Conditions of use 
low energy less than 170 kJ/100 g for solids or 80 kJ/100 ml for liquids 
low sodium less than 0.12 g of sodium per 100 g or per 100 ml 
(different limits for waters) 
source of fibre at least 3 g of fibre per 100 g or at least 1.5 g of fibre per 100 kcal 
high fibre at least 6 g of fibre per 100 g or at least 3 g of fibre per 100 kcal 
source of vitamins or 
minerals 
a significant amount1 of vitamins or minerals 
high in vitamins or minerals at least twice the amount of ‘source of vitamins or minerals’  
source of omega-3 fatty 
acids 
at least 0.3g alpha-linolenic acid per 100g and per 100kcal, or 
at least 40mg of the sum of eicosapentaenoic acid and 
docosahexaenoic acid per 100g and per 100kcal.  
high omega-3 fatty acids at least 0.6g alpha-linolenic acid per 100g and per 100kcal, or 
at least 80mg of the sum of eicosapentaenoic acid and 
docosahexaenoic acid per 100g and per 100kcal.  
Note: 1As a rule, 15 % of the recommended allowance specified in the Annex of Directive 90/496/EEC on 
nutrition labelling for foodstuffs supplied by 100 g or 100 ml (or per package if the package contains only a 
single portion) should be taken into consideration in deciding what constitutes a significant amount. 
Table 2. Examples of nutrition claims and the conditions applying to them (EC 2006) 
Labelling of the content of vitamins and minerals must also comply with the Council 
Directive 90/496/EEC on nutrition labelling for foodstuffs, which was amended in 2008. In this 
directive vitamins and minerals which may be declared on labels and their recommended 
daily allowances (RDAs) are set (Table 3).  
 
Vitamins RDA D-A-CH 
RI/AI1 
Minerals and trace 
elements 
RDA D-A-CH 
RI/AI1 
Vitamin A (μg)  800 1,000 Potassium (mg)  2,000 2,000 
Vitamin D (μg)  5 5 Chloride (mg)  800 830 
Vitamin E (mg)  12 14 Calcium (mg)  800 1,000 
Vitamin K (μg)  75 70 Phosphorus (mg)  700 700 
Vitamin C (mg)  80 100 Magnesium (mg)  375 350 
Thiamin (mg)  1.1 1.2 Iron (mg)  14 10 
Riboflavin (mg)  1.4 1.4 Zinc (mg)  10 10 
Niacin (mg)  16 16 Copper (mg)  1 2.0-5.0 
Vitamin B6 mg)  1.4 1.5 Manganese (mg)  2 1.0-1.5 
Folic acid (μg)  200 400 Fluoride (mg)  3.5 3.8 
Vitamin B12 μg)  2.5 3 Selenium (μg)  55 30-70 
Biotin (μg)  50 30-60 Chromium (μg)  40 30-100 
Pantothenic acid (mg) 6 6 Molybdenum (μg)  50 50-100 
   Iodine (μg) 150 150-200 
Notes: 1RI- Recommended intake, AI- Estimated value for adequate intake (provided value for adult 
men, 25-51 years). 
Table 3. Vitamins and minerals which may be declared and their recommended daily 
allowances (RDAs) as set in Council Directive 90/496/EEC on nutrition labelling for 
foodstuffs (amended in 2008) in comparison to D-A-CH reference values (D-A-CH 2002) 
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4.2 Health claims 
Regulation (EC) 1924/2006 defines health claim as any claim which states, suggests or implies 
that a relationship exists between a food category, a food or one of its constituents and 
health. All health claims should be authorised and included in the list of authorised claims. 
The quantity of the food and pattern of consumption required to obtain the claimed 
beneficial effect should be included in the labelling and reasonably expected to be consumed 
in context of a varied and balanced diet. The claim must be specific, based on generally 
accepted scientific data and well understood by the average consumer. Reference to general, 
non-specific benefits of the nutrient or food for overall good health or health-related well-
being may only be made if accompanied by a specific health claim (EC 2006). All authorised 
health claims are listed in a public Community Register of nutrition and health claims made on 
food which includes the wordings of claims and the conditions applying to them, together 
with any restrictions. Basically, the regulation distinguishes three categories of health claims 
(Table 4). General function claims describe the role of a food in body functions, including 
the sense of hunger or satiety and not referring to children, while disease risk reduction 
claims state that the consumption of a food or food constituent significantly reduces a risk 
factor in the development of a human disease. The regulation also mentions claims referring 
to children's development and health, for which no further definition is given. 
 
General function 
health claims 
Claims referring to 
children's development and 
health 
Reduction of disease risk 
claims 
Claims not referring to children 
and describing the role of a 
nutrient or other substance in 
growth, development and the 
functions of the body; or 
psychological and behavioural 
functions; or slimming or 
weight control or a reduction in 
the sense of hunger or an 
increase in the sense of satiety or 
to the reduction of the available 
energy from the diet. 
No further definition 
provided. 
Claims that state, suggest or 
imply that the consumption 
of a food category, a food or 
one of its constituents 
significantly reduces a risk 
factor in the development 
of a human disease. 
Table 4. Types of health claims according to EC regulations (EC 2006) 
5. Evaluation and authorisation of health claims 
The regulation requires authorization of all health claims by the European Commission 
through the Comitology procedure, following scientific assessment and verification of a 
claim by the European Food Safety Authority (EFSA) (Pravst 2010). Claims referring to 
children's development and health, reduction of disease risk claims and general function 
claims which are based on newly developed scientific evidence are submitted directly by 
companies. In cases where health claim substantiation is based on (unpublished) proprietary 
data and if a claim cannot be substantiated without such data, the applicant can request 5 
years of protection of such data.  
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In addition to the described procedure of health claims submission by applicants, all health 
claims which were on the market prior to 2006 were included in the so-called Article 13 
evaluation process. Lists of general function claims on the market were provided by EU 
member states in collaboration with the industry and included in a consolidated list which 
formed the basis for the EFSA evaluation. In 2009 it became clear that the process of 
evaluating existing general function health claims would be much more demanding than 
expected. After examining over 44 000 claims supplied by the EU member states, the EFSA 
has received a consolidated list of over 4600 general function claims which entered the 
evaluation process. The evaluation of most claims was finished in 2011 with 341 published 
scientific opinions, and providing scientific advice for 2758 general function health claims, 
about 20% being favourable. While some claims were withdrawn, about 1500 claims on so-
called botanicals have been placed on hold by the European Commission pending further 
consideration on how to proceed with these. 
Scientific and technical guidance for the preparation and presentation of an application for 
authorisation of a health claim (EFSA 2011c) and General guidance for stakeholders on the 
evaluation of health claims (EFSA 2011a) were prepared by the EFSA. Scientific substantiations 
of claims are performed by taking into account the totality of the available pertinent 
scientific data and by weighing up the evidence, in particular whether: 
- the effect is relevant for human health;  
- there is an established cause-and-effect relationship between the consumption of the 
food and the claimed effect in humans; 
- the effect has been shown on a study group which is representative of the target 
population; and 
- the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet. 
 
 
Fig. 2. Key questions addressed by the EFSA in the scientific evaluation of health claims 
(EFSA 2011a) 
The process of the implementation of health claims legislation has involved a steep learning 
curve which is far from complete. While the EFSA has had to cope with an unprecedented 
and unforeseen workload, coupled with very short deadlines, the industry is financing 
expensive trials which are often still not being performed using standards that would enable 
successful substantiation. More specific guidance is therefore being released to help industry 
No
No
No
Yes
Yes
Yes
Is the claimed effect sufficiently
defined and is it a beneficial 
physiological effect?
Is the food / constituent
sufficiently defined and 
characterised?
Have pertinent human studies
been presented to substantiate 
the claim?
The NDA Panel
weighs the evidence
of all pertinent studies 
presented.
A cause-and-effect 
relationship has 
not been 
Established.
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to substantiate health claims, starting with Guidance for health claims related to gut and immune 
function (EFSA 2011b). Guidance for health claims related to (1) antioxidants, oxidative 
damage and cardiovascular health, (2) bone, joints and oral health, (3) appetite ratings, 
weight management and blood glucose concentrations, (4) physical performance, and (5) 
cognitive function is also being developed. The key questions addressed by the EFSA in the 
scientific evaluation of health claims are presented in Fig. 2. 
5.1 The wording of a health claim 
The wording of a health claim must be specific, it must reflect the scientific evidence and it 
must be well understood by the average consumer. In the process of the scientific evaluation 
the EFSA can propose changing the wording to reflect the scientific evidence, but such 
wording is sometimes hard to understand by the general population. An example of such a 
procedure can be shown with a health claim for specific water-soluble tomato concentrate 
and maintenance of a healthy blood flow (Table 5). The EFSA considered that the wording 
which was proposed by the applicant did not reflect the scientific evidence because only 
measures of platelet aggregation have been used, whereas blood flow and circulation also 
depend on many other factors. It changed the wording to reflect the scientific evidence, 
although the Commission later reworded it to be understood by consumers (Pravst 2010).  
 
 Claim wording 
Applicant proposal: Helps to maintain a healthy blood flow and benefits circulation 
EFSA’s proposal: Helps maintain normal platelet aggregation 
Authorised by the EC: Helps maintain normal platelet aggregation, which contributes 
to healthy blood flow 
Table 5. The wording of a health claim for specific water-soluble tomato concentrate and 
maintenance of a healthy blood flow (EFSA 2009; Pravst 2010). 
When discussing the wording of health claims it should also be noted that, for reduction of 
disease risk claims, the wording should refer to the specific risk factor for disease and not to 
disease alone.  
5.2 Food characterisation 
The sufficient characterisation of foods or food constituents is important for the proper 
scientific evaluation of a health claim application and must enable authorities to control the 
market. In the scientific evaluation process the characterisation is needed to identify the 
food or food constituent, to define the appropriate conditions of use, and to connect it with 
the provided scientific studies. These studies should be performed using the same food or 
food constituent (which should also be sufficiently characterised). The lack of 
characterisation was one of the most common reasons for the EFSA’s non-favourable 
opinions regarding general function claims (Pravst 2010). 
In relation to characterisation it is necessary to distinguish between a specific formulation, 
specific constituent and a combination of constituents. All combinations must be 
characterised in detail, particularly in relation to the active constituents. Beside the physical 
and chemical properties and the composition, the analytical methods must also be provided 
(EFSA 2011a). In cases where variations in composition could occur, variability from batch 
to batch should be addressed together with stability with respect to storage conditions 
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during shelf life (EFSA 2011a). Where applicable it is useful to show that a constituent is 
bioavailable and provide a rationale of how the constituent reaches the target site. 
For microorganisms genetic typing should be performed at the strain level with 
internationally accepted molecular methods and the naming of strains according to the 
International Code of Nomenclature. Depositing samples in an internationally recognised 
culture collection for control purposes has been suggested (EFSA 2011a). The stability of the 
microorganisms and the influence of the food matrix on their activity should be studied. 
For plant products the scientific name of the plant should be specified, together with the 
part of the plant used and details of the preparation used, including details of the extraction, 
drying etc. It is beneficial when the applicant can show that the composition of the plant-
derived product can be controlled by analyses of specific chemical ingredients. For example, 
the above mentioned specific tomato concentrate was characterised on the basis of a clearly 
described production manufacturing process of tomatoes (Lycopersicum esculentum) together 
with a detailed chemical specification of the most important components and demonstrated 
batch-to-batch reproducibility (EFSA 2009). Chemical compounds which have been shown 
to have a beneficial effect in vitro were identified and quantified using the HPLC-MS 
technique, and the presence of unspecified constituents was limited. Several chemical and 
physical characteristics were assessed during stability testing, including breakdown 
products and the microbiological status. The bioactive components were shown to survive 
and to retain their activity in vitro over typical product shelf lives and when the product was 
included in specified matrixes. 
 
Study population Function 
Subjects with untreated hypertension 
 
maintaining normal blood pressure  
(for general population) 
Overweight and obese subjects weight reduction  
(for general population) 
Patients with functional constipation  bowel function  
(for general population) 
Irritable Bowel Syndrome (IBS) 
patients 
bowel function  
(for general population) 
Irritable Bowel Syndrome (IBS) 
patients 
gastro-intestinal discomfort  
(for general population) 
Subjects with immunosuppression  immune function  
(for population groups considered to be at risk 
of immunosuppression) 
Table 6. Some specific study populations which were found as appropriate for scientific 
substantiation of health claims (EFSA 2011b; Pravst 2010) 
5.3 Specific conditions of use 
The quantity of the food or food constituent and pattern of consumption must be specified 
together with possible warnings, restrictions on use and directions for use. It is important 
that the consumer can consume enough food as part of a balanced diet to obtain the claimed 
effect (EFSA 2011a). The target population must be specified and in relation to this, it is 
critical that the specific study group in which the evidence was obtained is also 
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representative of the target population for which the claim is intended (Pravst 2010). A 
key question is whether the results of studies on patients can be extrapolated to the target 
population. A judgement on this is made on a case-by-case basis, but in most cases 
patients were not found to be an appropriate study group. Usually, such studies are not 
considered as pertinent. In cases where studies are not performed on a representative of 
the target population, evidence must be provided that the extrapolation can be performed. 
No scientific conclusions can be drawn from studies on patients with genetically and 
functionally different cells and tissues. Some examples of specific study populations 
which were found as appropriate for scientific substantiation of health claims are listed in 
Table 6. 
5.4 Relevance of the claimed effect 
The claimed effect should be clearly defined and relevant to human health (Pravst 2010). 
This can be demonstrated with the example of the Caralluma fimbriata extract, and its effect 
on one’s waist circumference (EFSA 2010c). Studies showed a statistically significant 
reduction in waist circumferences, but a reduction in one’s waist circumference is not a 
beneficial physiological effect if it is not accompanied by an improvement in the adverse 
health effects of excess abdominal fat. On the contrary, only a slight improvement in 
parameters which are widely accepted as important to human health can be recognised as 
key evidence, such as in the case of a general functional claim for the role of omega-3 in 
maintaining normal blood pressure (EFSA 2009i). The EFSA concluded that high doses (3 g 
per day) of docosahexaenoic (DHA) and eicosapentaenoic acid (EPA) may have smaller, but 
statistically significant, effects in normotensives of about 1 mmHg; better results were 
observed in subjects with untreated hypertension. 
5.5 Scientific substantiation of the claimed effect 
Human data are critical for substantiating a claim and particular attention is paid to whether 
such studies are pertinent to the claim. Studies need to be carried out with the subject 
product with similar conditions of use in a study group representative of the population 
group and using an appropriate outcome measure of the claimed effect (EFSA 2011a). Using 
appropriate outcome measures can be a challenge because a limited number of validated 
biomarkers is available (Cazaubiel and Bard 2008). Biomarkers are characteristics that are 
objectively measured and evaluated as indicators of normal biological processes, 
pathogenic processes or pharmacologic responses to therapeutic intervention. Well-
performed human intervention trials are particularly important for successful 
substantiation. Double-blind, randomised, placebo-controlled trials are considered the 
gold standard not only for the substantiation of disease risk reduction claims but also for 
general function claims (Pravst 2010). During the scientific evaluation such trials are 
assessed critically to assure there are no weaknesses. A good study design, proper 
performance, well-defined statistics and appropriate statistical power (enough subjects) 
are key issues in this context. In some cases, non-blind studies are also acceptable, 
particularly in the case of non-processed foods where blinding is not possible. This was 
confirmed recently in the case of a general function claim application for dried plums and 
their laxative effect (EFSA 2010h) – a study in which subjects free of gastrointestinal and 
eating disorders were randomised to consume either dried plums or grape juice was 
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found to be pertinent. Nevertheless, taking the results of other studies into account there 
was insufficient evidence to establish a cause-and-effect relationship.  
Human observational studies and data from studies in animals or model systems are 
considered only as supporting evidence.  
6. Components of functional foods 
As already mentioned, limiting certain food components or simply delivering nutrient 
intake cannot be regarded as a healthy diet. However, the functional effects of foods are 
usually studied in relation to their composition and bioactive components (in some cases 
also with isolated components). In this chapter over 300 scientific opinions on general 
function health claims (for the ones which are currently present on the European market) 
were reviewed. On the basis of these opinions and discussion within member states the 
European Commission will prepare a list of substantiated health claims and their 
conditions of use. 
6.1 Vitamins, minerals and trace elements 
When talking about essential nutrients we need to consider that there is a well-established 
consensus among scientists on many functions of such nutrients. In the evaluation of health 
claims we may rely on such a consensus and in such cases it may not be necessary to review 
the primary scientific studies on the claimed effect of the food (EFSA 2011a). On such bases 
many general function health claims for vitamins, minerals and trace elements received 
favourable opinions in the assessment process (Table 7). In most cases the proposed 
condition of use of such a claim is that the food is at least a source of the nutrient (15% of the 
RDA specified in Table 3 per 100 g or 100 ml, or per package if the package contains only a 
single portion). 
Several essential nutrients were recognised to possess antioxidant activity, which is 
commonly communicated on functional foods. While the current evidence does not support 
the use of antioxidant supplements in the general population or in patients with certain 
diseases (Bjelakovic et al. 2008), some food components are indeed included in the 
antioxidant defence system of the human body, which is a complex network including 
endogenous antioxidants and dietary antioxidants, antioxidant enzymes, and repair 
mechanisms, with mutual interactions and synergetic effects among the various components 
(EFSA 2009{). For example, vitamin C functions physiologically as a water-soluble 
antioxidant and plays a major role as a free radical scavenger. On such a basis a cause-and-
effect relationship has been established between the dietary intake of vitamin C and the 
protection of DNA, proteins and lipids from oxidative damage. Other antioxidants include 
vitamin E, riboflavin, copper, manganese and selenium (Table 7). 
A series of vitamins and trace elements is involved in the functioning of the human immune 
system, but their ability to promote immunity function is questionable, especially in 
populations with adequate intake. For example, zinc deficiency is associated with a decline 
in most aspects of immune function; lymphopaenia and thymic atrophy are observed, cell 
mediated and antibody mediated responses are reduced (EFSA 2009~). Additionally, zinc 
deficiency appears to induce apoptosis, resulting in a loss of B-cell and T-cell precursors 
within the bone marrow. Adequate zinc status is necessary for natural killer cell function 
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and zinc deficiency renders people more susceptible to infections. A cause-and-effect 
relationship has been established between the dietary intake of zinc and the normal function 
of the immune system but it was noted that there is no evidence for inadequate intake of 
zinc in the general EU population (EFSA 2009~). A function in the immune system was also 
recognised for copper, selenium and various vitamins (vitamins A, D, B6, B12, C and folate) 
(Table 7). In the case of vitamin D it was also concluded that it contributes to healthy 
inflammatory response (EFSA 2010ƒ). 
 
Health realtionship1 Vitamins Minerals and trace elements 
Function as 
antioxidant 
Vitamin E (EFSA 2010„) 
Riboflavin (EFSA 2010}) 
Vitamin C (EFSA 2009{) 
Cu (EFSA 2009h) 
Mn (EFSA 2009r) 
Se (EFSA 2009v) 
Function in immune 
system 
Vitamin A (EFSA 2009x) 
Vitamin D (EFSA 2010ƒ) 
Vitamin B6 (EFSA 2009z) 
Folate (EFSA 2009k) 
Vitamin B12 (EFSA 2009y) 
Vitamin C (EFSA 2009{) 
Cu (EFSA 2009h) 
Fe (EFSA 2009n) 
Se (EFSA 2009v) 
Zn (EFSA 2009~) 
Function in brain or 
nervous system 
Thiamine (EFSA 2009c; EFSA 2010 ) 
Riboflavin (EFSA 2010}) 
Niacin (EFSA 2009s; EFSA 2010w) 
Pantothenate (EFSA 2009t; EFSA 
2010x) 
Vitamin B6 (EFSA 2009z; EFSA 2010)
Folate (EFSA 2010j) 
Vitamin B12 (EFSA 2010€) 
Biotin (EFSA 2010d) 
Vitamin C (EFSA 2009{; EFSA 2010‚) 
Cu (EFSA 2009h) 
Fe (EFSA 2009n; EFSA 2010n) 
I (EFSA 2010m) 
K (EFSA 2010{) 
Mg (EFSA 2009q; EFSA 
2010r) 
Zn (EFSA 2009~) 
Function in bone or 
teeth 
Vitamin D (EFSA 2009g; EFSA 2009|)
Vitamin K (EFSA 2009}) 
Ca (EFSA 2009f; EFSA 2009g) 
Mg (EFSA 2009q) 
P (EFSA 2009u) 
Cu (EFSA 2009h) 
K (EFSA 2010{) 
Mn (EFSA 2009r) 
Zn (EFSA 2009~) 
F- (EFSA 2009j) 
Function in skin, hair 
or connective tissues 
Vitamin A (EFSA 2009x) 
Riboflavin (EFSA 2010}) 
Niacin (EFSA 2009s) 
Biotin (EFSA 2009e) 
Cu (EFSA 2009h) 
I (EFSA 2009m) 
Se (EFSA 2009v; EFSA 2010~) 
Zn (EFSA 2010†) 
Function in vision Vitamin A (EFSA 2009x) 
Riboflavin (EFSA 2010}) 
Zn (EFSA 2009~) 
Function in muscle Vitamin D (EFSA 2010ƒ) 
 
Ca (EFSA 2009f) 
Cu (EFSA 2009h) 
K (EFSA 2010{) 
Mg (EFSA 2009q) 
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Health realtionship1 Vitamins Minerals and trace elements 
Function in blood, 
haemoglobin and 
oxygen transport 
Vitamin A (EFSA 2009x) 
Vitamin K (EFSA 2009}) 
Riboflavin (EFSA 2010}) 
Vitamin B6 (EFSA 2009z) 
Folate (EFSA 2009k) 
Vitamin B12 (EFSA 2009y) 
Vitamin C (EFSA 2009{) 
Ca (EFSA 2009f) 
Cu (EFSA 2009h) 
Fe (EFSA 2009n) 
Function in cell 
division & 
differentiation 
Vitamin A (EFSA 2009x) 
Vitamin D (EFSA 2009|) 
Folate (EFSA 2009k) 
Vitamin B12 (EFSA 2009y) 
Ca (EFSA 2010e) 
Fe (EFSA 2009n) 
Mg (EFSA 2009q) 
Zn (EFSA 2009~) 
Function in regulation 
of hormones 
Pantothenic acid (EFSA 2009t) 
Vitamin B6 (EFSA 2010) 
I (EFSA 2009m) 
Se (EFSA 2009v) 
Zn (EFSA 2010†) 
Function in 
metabolism of 
nutrients 
Thiamine (EFSA 2009c) 
Riboflavin (EFSA 2010}) 
Niacin (EFSA 2009s) 
Pantothenate (EFSA 2009t) 
Vitamin B6 (EFSA 2009z; EFSA 2010)
Vitamin B12 (EFSA 2009y) 
Biotin (EFSA 2009e) 
Vitamin C (EFSA 2009{) 
Ca (EFSA 2009f) 
Cr (EFSA 2010f) 
Cu (EFSA 2009h) 
Fe (EFSA 2009n) 
I (EFSA 2009m) 
Mg (EFSA 2009q) 
Mn (EFSA 2009r) 
Mo (EFSA 2010v) 
P (EFSA 2009u) 
Zn (EFSA 2009~; EFSA 2010†) 
Notes: 1 See references for details on specific health claims. A reference to general, non-specific benefits 
of the nutrient for overall good health or health-related well-being may only be made if accompanied by 
a specific health claim. 
Table 7. Selection of general function health claims for vitamins, minerals and trace elements 
as assessed by the EFSA 
According to a recent Irish study, brain function is most commonly communicated on soft 
drinks. In fact, all known water-soluble vitamins, and several minerals and essential 
elements (copper, iron, iodine, potassium, magnesium and zinc) are recognised as important 
in this context (Table 7). Functions which were favourably assessed by the EFSA include 
maintenance of normal function of the nervous system, cognitive function, psychological 
functions, neurological functions, and reduction of tiredness and fatigue (depending on the 
particular nutrient). The role of vitamin B6 in the maintenance of mental performance was 
also evaluated. Human studies have shown the effect of vitamin B6 on symptoms of 
depression, cognition, ageing, premenstrual syndrome and memory performance, however 
the daily doses for supplementation ranged from 40 - 600 mg (EFSA 2009z), well above the 
Tolerable Upper Intake Level (UL) (25 mg). Such a claim is not appropriate because it would 
encourage excess consumption of vitamin B6. 
The effect of nutrition on bone health is well established. The maximum attainment of peak 
bone mass achieved during growth and the rate of bone loss with advancing age are the two 
principal factors affecting adult bone health. With increasing life expectancy the 
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epidemiology of bone-health related conditions is changing drastically and represents a 
major public health threat in the Western world. The careful formulation of functional foods 
represents an important step in the promotion of bone health and consequently on the 
quality of one’s life, but to minimise health risks for consumers both the positive and the 
negative effects of active ingredients should be considered when developing such products. 
Calcium and vitamin D are considered the most important constituents of functional foods 
for the support of bone health (Earl et al. 2010; Palacios 2006) and received favourable 
opinions for maintaining normal bone and teeth. Additionally, the role of vitamin D in 
maintaining normal blood calcium concentrations and absorption and utilisation of Ca and 
P was confirmed (EFSA 2009|). In the last decade, the role of vitamin K in Ǆ-carboxylation of 
osteocalcin has also been recognised (Ikeda et al. 2006; Katsuyama et al. 2004) as about 10-
30% of osteocalcin in the healthy adult population is in an under-carboxylated (and 
therefore inactive) state (Vermeer et al. 2004). Other nutrients recognised in maintaining 
normal bone health are magnesium, zinc, manganese, potassium, copper and phosphorus 
(Table 7). However, the enrichment of (functional) foods or drinks with phosphorus is 
controversial as its intake can easily exceed the recommendations and a bigger intake might 
have adverse effects on bone health (Pravst 2011b). Therefore, both health and ethical 
concerns arise as to whether such claims should be allowed, even though science is not yet 
clear on this issue. A useful solution in such cases would be to authorise the claim with 
more specific conditions of use.  
Most of the nutrients with a function in bone health were also recognised as important in the 
maintenance of normal teeth (vitamin D, calcium, magnesium and phosphorus). 
Additionally, the beneficial role of fluoride for tooth health (by counteracting 
hydroxyapatite demineralisation and supporting remineralisation) is widely accepted as 
fluoride can replace hydroxyl ions in the hydroxyapatite crystal lattice of a tooth’s tissues 
and make it more resistant to acid exposure (EFSA 2009j). 
Biotin is the only vitamin that has received a favourable opinion for its role in the 
maintenance of normal hair (EFSA 2009e). While there were no studies available in which 
improvement in hair loss and hair quality were studied using objective methods, it is known 
that the symptoms of biotin deficiency include thinning hair and progression to a loss of all 
hair, including eyebrows and lashes (EFSA 2009e). Copper, selenium and zinc were also 
recognised as important in the maintenance of normal hair (Table 7). Other functions of 
these nutrients include the maintenance of normal nails, skin or mucous membranes, while 
a role in the normal formation of connective tissue was determined only for manganese 
(EFSA 2010s) and copper (EFSA 2009h). 
Vitamin A and compounds with pro-vitamin A activity (i.e. beta-carotene) are recognised to 
have a function in maintaining normal vision. Retinal is required by the eye for the 
transduction of light into neural signals which are necessary for vision and without an 
adequate level of vitamin A in the retina night blindness occurs (EFSA 2009x). In a different 
way vitamin A deficiency leads to a reduction in mucus production by the goblet cells of the 
conjunctival membranes and the cornea becomes dry. Riboflavin (EFSA 2010}) and zinc 
(EFSA 2009~) also received favourable opinions. 
With muscle weakness being a major clinical syndrome of vitamin D deficiency, vitamin D is 
the only vitamin with a favourable opinion about its role in the maintenance of normal muscle 
function (EFSA 2010ƒ). Clinical symptoms of the deficiency include proximal muscle 
weakness, diffuse muscle pain and gait impairments such as a waddling way of walking. 
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Dietary intake of calcium, magnesium, potassium and copper was also connected with muscle 
function (Table 7). In a similar manner the importance of sodium was confirmed; however, 
current sodium intake in the general EU population is more than adequate and directly 
associated with a greater likelihood of increased blood pressure, which in turn has been 
directly related to the development of cardiovascular and renal diseases (EFSA 2011y). 
Promoting sodium intake with the use of health claims is in obvious conflict with current 
targets for a reduction in dietary sodium intakes (Cappuccio and Pravst 2011). 
Several nutrients have received favourable opinions for their function in blood, formation of 
haemoglobin or oxygen transport (Table 7). In haemoglobin, iron allows reversible binding 
of oxygen and its transport in the erythrocytes to the tissues. The most common 
consequence of iron deficiency is microcytic anaemia. The role of iron in oxygen transport, 
normal formation of red blood cells and haemoglobin is obviously well established (EFSA 
2009n). Interestingly, there is still a significant prevalence of iron deficiency in Europe, 
especially among children and women of reproductive age and during pregnancy. Because 
dietary iron is absorbed as Fe2+ (and not as Fe3+), reducing agents, including vitamin C, 
promote non-haem iron absorption by keeping it reduced. The function of vitamin C and 
non-haem iron absorption therefore received a favourable opinion (EFSA 2009{). Other 
vitamins and minerals with a confirmed cause-and-effect relationship were vitamin A in the 
metabolism of iron, vitamin K and calcium in normal blood coagulation, folate in normal 
blood formation, copper in normal iron transport, and riboflavin, vitamin B6 and B12 in the 
normal formation of red blood cells.  
Other specific functions of vitamins, minerals and trace elements which are rarely 
communicated on food labelling were also included in the evaluation process. The ones with 
favourable outcomes include a function in cell division & differentiation, regulation of 
hormones and metabolism of nutrients (Table 7). In addition, some of the following very 
specific health claims were assessed: selenium and the maintenance of normal 
spermatogenesis (EFSA 2009v); zinc and normal fertility and reproduction, normal DNA 
synthesis; normal vitamin A metabolism and normal acid-base metabolism (EFSA 2009~); 
vitamin C and normal collagen formation (EFSA 2009{) and regeneration of the reduced 
form of vitamin E (EFSA 2010‚); vitamin B6 and normal glycogen metabolism (EFSA 2009z) 
and normal cysteine synthesis (EFSA 2010); folate and normal maternal tissue growth 
during pregnancy (EFSA 2009k); phosphorus and normal functioning of cell membranes 
(EFSA 2009u); magnesium and electrolyte balance (EFSA 2009q); and, calcium and normal 
functioning of digestive enzymes (EFSA 2009f).  
Vitamin B6, B12 and folic acid were recognised as important for their contribution to normal 
homocysteine metabolism (EFSA 2009k; EFSA 2010€; EFSA 2010). Deficiencies in these 
vitamins lead to impaired homocysteine metabolism causing mild, moderate, or severe 
elevations in plasma homocysteine (depending on the severity of the deficiency) as well as 
the coexistence of genetic or other factors that interfere with homocysteine metabolism 
(EFSA 2010). In addition to these vitamins, a contribution to normal homocysteine 
metabolism has also been established for betaine (EFSA 2011g) and choline (EFSA 2011l). 
Choline can function as a precursor for the formation of betaine, which acts as a methyl 
donor in the remethylation of homocysteine in the liver by the enzyme betaine-
homocysteine methyltransferase (EFSA 2011g). Choline can be biosynthesised in our liver 
and is therefore not a vitamin; however, most men and postmenopausal women need to 
consume it in their diets (Zeisel and Caudill 2010). The nutritional need for choline greatly 
www.intechopen.com
 
Scientific, Health and Social Aspects of the Food Industry 
 
180 
depends on gender, age and genetic polymorphisms. For this reason the EFSA was unable 
to propose conditions of use; however, it was noted that a nutrient content claim has been 
authorised in the US, based on the adequate intake for adult males (550 mg of choline per 
day). Furthermore, choline has also received a favourable opinion for the maintenance of 
normal liver function and its contribution to normal lipid metabolism (EFSA 2011l). In 
relation to betaine it must be mentioned that the application for the use of betaine as a novel 
food ingredient in the EU was rejected, mainly due to concerns over the safety of betaine 
with long term use (EFSA 2005). Despite this, betaine as a constituent of traditional foods is 
not considered a novel food. 
In practice, a functional food can also be a food from which a component has been removed 
to provide benefits not otherwise available (Ashwell 2002). Good examples of such foods are 
foods low or very low in sodium, whose consumption helps to maintain normal blood 
pressure (EFSA 2011p). In fact, sodium intake and blood pressure demonstrate a close and 
consistent direct relationship (Cappuccio and Pravst 2011) and there is extensive evidence to 
support this (He and MacGregor 2010). A 4.6g reduction in daily dietary salt intake 
decreases BP by about 5.0/2.7 mmHg in hypertensive individuals and by 2.0/1.0 mmHg in 
normotensive people. Dose-response effects have been consistently demonstrated in adults 
and children (He and MacGregor 2003). A 5g higher salt intake is associated with a 17% 
greater risk of total cardiovascular disease and a 23% greater risk of stroke (Strazzullo et al. 
2009). 
6.2 Fats, fatty acids and fatty acid composition 
Fats are a major contributor to total energy intakes in most Western diets, supplying 35-40% of 
food energy through the consumption of 80-100g of fat per day (Geissler and Powers 2005). All 
fat sources contain mixtures of saturated, monounsaturated and polyunsaturated fatty acids, 
but the proportions vary significantly according to the source. Besides being a source of 
energy, fats also play other diverse roles in the human body. Two fatty acids, linoleic acid and 
ǂ-linolenic acid are essential in the human diet as they cannot be synthesised in mammalian 
tissues. The human body can synthesise eicosapentaenoic acid (EPA) and docosahexaenoic 
acid (DHA) from ǂ-linolenic acid, but the synthesis is not very efficient. 
The balance between saturated and unsaturated fats in the diet is known to influence 
circulating cholesterol concentrations (WHO 2003). Current dietary recommendations for 
adults in the EU are to limit intake of fats to 20-35 energy % (E%) and to keep the intake of 
saturated fatty acid (SFA) and trans fatty acid as low as possible (EFSA 2010b). The 
proposed adequate intakes are: 4 E% for linolenic acid; 0.5 E% for ǂ-linolenic acid (ALA); 
and 250 mg for EPA+DHA. 
In Table 8 the proposed conditions of use of health claims related to fats, fatty acids and 
fatty acid composition are listed. Cholesterol related claims are one of the most common 
categories of health claims on the market (Lalor et al. 2010). The role of fatty acid 
composition in cholesterol management has been confirmed and the proposed conditions of 
use should stimulate a reduced intake of saturated fatty acids also through product 
reformulation (EFSA 2011o; EFSA 2011{). Such a product should contain at least 30% less 
saturated fatty acids compared to a similar product. The role of linolenic and ǂ-linolenic 
acid in cholesterol management also received favourable opinions, where a food contains at 
least 15% of the proposed labelling reference intake.  
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Food 
component1 
Function Conditions of use Reference 
Fat Normal absorption of fat-
soluble vitamins 
no conditions of use can be 
defined 
(EFSA 2011n) 
Saturated 
fatty acids 
Management of cholesterol reduced amounts of saturated 
fatty acids by at least 30% 
compared to a similar product 
(EFSA 2011{) 
(EFSA 2011o) 
Linoleic acid Management of cholesterol 15% of the proposed labelling 
reference intake values of 10g 
linoleic acid per day 
(EFSA 2009p) 
ALA Management of cholesterol 15% of the proposed labelling 
reference intake value of 2g 
ALA per day 
(EFSA 2009b) 
Plant sterols Management of cholesterol 0.8g per day (EFSA 2010z) 
DHA/EPA Management of blood 
triglycerides 
2-4g per day (EFSA 2009i) 
 Management of blood 
pressure 
3g per day (EFSA 2009i) 
 Heart health 250mg per day (EFSA 2010i) 
DHA Vision 250mg per day (EFSA 2010g) 
 Brain function 250mg per day (EFSA 2010g) 
Notes: 1ALA - ǂ-linolenic acid; DHA - docosahexaenoic acid; EPA - eicosapentaenoic acid. 
Table 8. Conditions of use health claims related to fats, fatty acids and fatty acid 
composition as assessed by the EFSA 
Plant sterols have been known for several decades to cause reductions in plasma cholesterol 
concentrations (St Onge and Jones 2003). These are also well known by consumers and are 
one of the most well-known functional ingredients. Plant sterols are structurally very similar 
to cholesterol, except that they always contain a substituent at the C24 position on the sterol 
side chain (Ling and Jones 1995). It is generally assumed that cholesterol reduction results 
directly from the inhibition of cholesterol absorption through the displacement of 
cholesterol from micelles. Their concentrations in mammalian tissue are normally very low - 
primarily due to poor absorption from the intestine and faster excretion from the liver 
compared to cholesterol (Ling and Jones 1995). The LDL-cholesterol lowering effects of plant 
sterols and stanols have been reviewed several times, lately by Demonty and co-workers 
(Demonty et al. 2008). In the general health claim evaluation process plant sterols and 
stanols were confirmed to be helpful in maintaining normal blood cholesterol levels when 
the food provides at least 0.8g of plant sterols or stanols daily in one or more servings (EFSA 
2010z). Such products may not be nutritionally appropriate for pregnant and breastfeeding 
women, or for children under the age of five (EFSA 2010z). It must be mentioned that the 
related reduction of disease risk claims were already authorised for both plant sterols and 
stanol esters. Lowering blood cholesterol and reference to cholesterol as a risk factor in the 
development of coronary heart disease can be communicated on foods which provide a 
daily intake of 1.5-2.4g plant sterols/stanols. Most studies of cholesterol lowering effects 
were conducted with plant sterols or stanols added to foods such as margarine-type 
spreads, mayonnaise, and dairy products. Studies are showing an increase in the 
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consumption of plant sterols in Europe. The consumption of foods enriched with plant 
sterols was recently studied in Belgium; the results indicate that plant sterol-enriched food 
products are also consumed by the non-target group and that efficient communication tools 
are needed to better inform consumers about the target group of enriched products, the 
advised dose per day and alternative dietary strategies to lower blood cholesterol level 
(Sioen et al. 2011). Although intakes of plant sterols have not produced significant adverse 
effects, it is not known whether constant consumption at high levels would have any toxic 
effects (St Onge and Jones 2003). It is therefore logical to advise the food industry to also 
formulate cholesterol-management foods with other effective functional ingredients, 
particularly with specific dietary fibres, being a more common constituent of the human diet 
(see chapter 6.3 Carbohydrates and dietary fibre). 
Intervention studies have demonstrated the beneficial effects of preformed n-3 long-chain 
polyunsaturated fatty acids (DHA, EPA) on recognised cardiovascular risk factors, such as a 
reduction in plasma triacylglycerol concentrations and blood pressure, albeit in quite high 
daily dosages (EFSA 2010b). The proposed daily dose for the management of blood 
triglycerides and the management of blood pressure is 2-4g and 3g of DHA and EPA 
respectively (Table 8). The question remains, however, as to whether such claims will be 
authorised. Lower daily dosages of DHA and EPA are required to maintain normal cardiac 
function (250mg DHA/EPA), normal vision and brain function (250 mg DHA). 
6.3 Carbohydrates and dietary fibre 
According to the degree of polymerisation we categorise carbohydrates into sugars 
(monosaccharides and disaccharides), oligosaccharides (3-9 residues), and polysaccharides 
with over 9 monomeric residues.  
6.3.1 Glycaemic carbohydrates 
Glycaemic carbohydrates are digested and absorbed in the human small intestine and 
provide glucose to body cells as a source of energy. According to their degree of 
polymerisation, these are sugars and some oligosaccharides and polysaccharides. The main 
glycaemic carbohydrates in the diet are glucose and fructose (monosaccharides), sucrose 
and lactose (disaccharides), malto-oligosaccharides and starch (polysaccharides) (EFSA 
2010a). Glycaemic carbohydrates provide about 40% of energy intake in average Western 
diets, with a desirable level at around 55% (Geissler and Powers 2005). Far more glycaemic 
carbohydrates are consumed in developing countries.  
Glucose is the preferred energy source for most body cells and the brain requires glucose for 
its energy needs. An intake of 130g of dietary glycaemic carbohydrates per day for adults is 
estimated to cover the glucose requirement of the brain (EFSA 2010a). In the health claim 
evaluation process a cause-and-effect relationship has been established between the 
consumption of glycaemic carbohydrates and the maintenance of normal brain function 
(EFSA 2011r). However, when talking about carbohydrates as constituents of functional 
foods we are usually discussing either lowering their amount or the functional properties of 
indigestible polysaccharides (dietary fibre). 
Sugar replacement in foods or drinks with xylitol, sorbitol, mannitol, maltitol, lactitol, 
isomalt, erythritol, D-tagatose, isomaltulose, sucralose or polydextrose was found to be 
efficient in the reduction of post-prandial blood glucose responses as compared to sugar-
containing products (EFSA 2011|). Lowering sugar levels is also considered beneficial in 
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maintaining the mineralisation of teeth (EFSA 2011s; EFSA 2011|). However, excessive 
amounts of polyols may result in a laxative effect and this should be communicated to the 
consumer with an appropriate (and mandatory) advisory statement. 
6.3.2 Dietary fibre 
Dietary fibre is mostly derived from plants and is composed of complex, non-starch 
carbohydrates and lignin that are not digestible within the small intestine – since mammals 
do not produce enzymes capable of their hydrolyses into constituent monomers (Turner and 
Lupton 2011). Dietary fibre is considered a non-nutrient and contributes no calories to our 
diet as it reaches the colon intact. However, in the colon dietary fibres are available for 
fermentation by the resident bacteria, and the metabolites released can be used to meet some 
of the energy requirements.  
Regulatory fibre is defined in Council Directive 90/496/EEC on nutrition labelling for foodstuffs 
as carbohydrate polymers with three or more monomeric units, which are neither digested 
nor absorbed in the human small intestine and belong to the following categories: (1) edible 
carbohydrate polymers naturally occurring in the food as consumed; (2) edible carbohydrate 
polymers which have been obtained from raw food material by physical, enzymatic or 
chemical means and which have a beneficial physiological effect demonstrated by generally 
accepted scientific evidence; (3) edible synthetic carbohydrate polymers which have a 
beneficial physiological effect demonstrated by generally accepted scientific evidence. The 
EFSA has evaluated several specific dietary fibres for their role in the management of 
cholesterol, glycaemic response and gut health (Table 9).  
The beneficial health effects of water-soluble dietary fibre mainly relate to their ability to 
improve viscosity of the meal bolus in the small intestine and thus to delay the absorption of 
nutrients. A lowering of blood cholesterol was established for beta-glucans, chitosan, 
glucomannan, hydroxypropyl methylcellulose (HPMC), pectins and guar gum when at least 
3-10g of fibre was consumed daily (Table 9). Among these, the lowest daily dosage (3g in 
one or more servings) is required for non-processed or minimally processed beta-glucans 
from specific sources (EFSA 2009d). The structural features of beta-glucans greatly influence 
their molecular shape (conformation) and the behaviour of the polysaccharide in a solution, 
including viscosity. The primary source of beta-glucans and the production processes 
therefore have a great impact on their functionality. Beta-glucans are widely distributed as 
non-cellulosic matrix phase polysaccharides in cell walls of the Poaceae, which consist of the 
grasses and commercially important cereal species (Burton and Fincher 2009). Chemically, 
these are (1,3;1,4)-ǃ-D-Glucans - as they consist of unbranched and unsubstituted chains of 
(1,3)- and (1,4)-ǃ-glucosyl residues. Their physicochemical and functional properties in cell 
walls are influenced by the ratio of (1,4)-ǃ-D-glucosyl residues to (1,3)-ǃ-D-glucosyl 
residues. An example of beta-glucans with a recognised cholesterol effect includes beta-
glucans from barley (AbuMweis et al. 2010; Talati et al. 2009), a cereal grain derived from 
the Hordeum vulgare. The proportion between ǃ-(1,3) and ǃ(1,4) linkages is 30 and 70%, 
respectively (Jadhav et al. 1998). In the polymer chain the blocks of 2 or 3 contiguous (1,4) 
linkages are separated by single (1,3) linkages; however, blocks of 2 or more adjacent (1,3) 
linkages are absent (Jadhav et al. 1998). Because the (1,3) linkages occur at irregular intervals 
the overall shape of the polysaccharide is irregular, which reduces its tendency to pack into 
stable, regular molecular aggregates and enable the formation of stable viscous solutions. It 
must be noted that beta-glucans are useful particularly in the production of hard functional 
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foods such as bread, toasts, pasta, extruded flakes, crisps etc. On the market there are also 
some beta-glucan-enriched liquid functional foods (i.e. yoghurts) and drinks with a labelled 
cholesterol management effect; however, the length of the polymeric chain of beta-glucans 
contained in such products is shortened with chemical or enzymatic procedures. Such an 
ingredient has a lower capacity to form viscous solutions, and consequently a lower 
efficiency. Thus, the use of a health claim is not allowed in these cases (EFSA 2009d). 
 
Dietary fibre Management of 
cholesterol 
Management of  
glycaemic response 
Gut health Reference 
Beta glucans 3g per day 
(non-processed 
beta-glucans) 
4g for each 30g of 
available 
carbohydrate  
(oats and barley beta-
glucans) 
high in fibre2 (EFSA 2009d) 
(EFSA 2011f) 
(EFSA 2011u) 
Chitosan 3g per day   (EFSA 2011k) 
Glucomannan 4g per day   (EFSA 2009l) 
HPMC1 5g per day 4g per meal  (EFSA 2010l) 
Pectins 6g per day 10g per meal  (EFSA 2010y) 
Guar gum 10g per day   (EFSA 2010k) 
Arabinoxylan   8g of arabinoxylan-
rich fibre per 100g of 
available 
carbohydrates  
 (EFSA 2011e) 
Resistant starch  14% of total starch as 
resistant starch 
(high carbohydrate 
baked foods) 
 (EFSA 2011w) 
Rye fibre   high in fibre4  (EFSA 2011x) 
Wheat bran fibre   high in fibre2  
10g per day3 
(EFSA 2010…) 
Notes: 1HPMC - hydroxypropyl methylcellulose; 2Increase in faecal bulk; 3Reduction in intestinal transit 
time; 4Changes in bowel function; Reference to general, non-specific benefits of the nutrient for overall 
good health or health-related well-being may only be made if accompanied by a specific health claim. 
Table 9. Conditions of use for general function health claims of various dietary fibres as 
proposed by the EFSA 
Decreasing the magnitude of elevated blood glucose concentrations after consuming 
carbohydrate-rich food is a critical target in the production of low glycaemic index (GI) 
foods. It is well established that the management of glycaemic responses is beneficial to 
human health, particularly for people with impaired glucose tolerance (which is common 
among the general population). Various specific dietary fibres were recognised as beneficial 
in the reduction of post-prandial glycaemic responses. In most cases, the rationale for such a 
function is, similar to cholesterol lowering, related to their ability to achieve improved 
viscosity of the meal bolus in the small intestine. This enables a delay in the absorption of 
sugars - which is considered beneficial as long as post-prandial insulinaemic responses are 
not disproportionally increased. In the evaluation process the EFSA found a cause-and-
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effect relationship between the mentioned effect and the consumption of beta-glucans from 
oats and barley, HPMC, pectins, arabinoxylan produced from wheat endosperm and 
resistant starch. Various conditions of use were proposed (Table 9). 
Both water-soluble and water-insoluble dietary fibres are also known to support gut health 
through changes in bowel function. Reduced transit time, more frequent bowel movements, 
increased faecal bulk or softer stools may be a beneficial physiological effect, provided these 
changes do not result in diarrhoea (EFSA 2011x). On the basis of such changes the functional 
role of rye fibre was confirmed to contribute to normal bowel function in foods providing at 
least 6g of such fibre per 100g (or at least 3g per 100kcal), being high in fibre (EFSA 2011x). 
The ability to increase faecal bulk has also been confirmed for wheat, oat and barley grain 
fibre (Table 9). Similar to the previous case, the proposed conditions of use are that the food 
is high in fibre. It is well established that the bulking effect of dietary fibre is closely related to 
the physico-chemical properties of the fibre, and in that way to the degree of fermentation 
by the gut microbiota in the large intestine (EFSA 2011u). The insoluble components of fibre 
are minimally degraded by colonic bacteria and thus remain to trap water, thereby 
increasing faecal bulk. In contrast, the bulking effects of soluble dietary fibre are determined 
by the higher extent of fermentation, and thus an increase in the bacterial mass in faeces 
(EFSA 2011u). A somewhat different support of gut health can be based on the ability of 
dietary fibre to reduce intestinal transit time. Such a function was found for wheat bran 
fibre, which increases the water holding capacity of the contents of the intestine, increases 
intestinal and pancreatic fluid secretion and thus increases the velocity of chyme 
displacement through the intestine if at least 10g per day is consumed (EFSA 2010…). A 
similar effect, but with a different mechanism of action, was also confirmed for lactulose – a 
synthetic sugar used in the treatment of constipation (EFSA 2010p). In the colon, lactulose is 
broken down to lactic acid and to small amounts of acetic and formic acids by the action of 
beta-galactosidases from colonic bacteria. This process leads to an increase in osmotic 
pressure and a slight acidification of the colonic content, causing an increase in stool water 
content and a softening of stools (EFSA 2010p). However, due to the medicinal use of 
lactulose in some EU countries the authorisation of such a health claim on foods is 
questionable.  
6.3.3 Prebiotics 
Prebiotics were defined as non-digestible food ingredients that beneficially affect the host by 
selectively stimulating the growth or activity of one or a limited number of bacterial species 
already resident in the colon, and thus attempt to improve host health (Gibson and 
Roberfroid 1995). An intake of prebiotics can modulate the colonic microbiota by increasing 
the number of specific bacteria and thus changing the composition of the microbiota. 
Consumers perceive prebiotics as having health benefits. The Guidance on the implementation 
of regulation No 1924/2006 on nutrition and health claims made on foods specifies that a claim is a 
health claim if, in the naming of the substance or category of substances, there is a 
description or indication of functionality or an implied effect on health. The examples 
provided include the claim contains prebiotic fibres. Such claims should therefore only be 
used if the food contains prebiotic fibres with a scientifically proven effect and when such a 
claim is accompanied by a specific health claim. In practice, this is not yet the case and such 
claims are still very common on the market. Only a few (prebiotic) fibres have received 
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favourable opinions from the EFSA. One example is the already-mentioned oat and barley 
grain fibres - whose bulking effects are determined by the higher extent of fermentation and 
thus an increase in the bacterial mass in faeces. On such a basis their ability to increase faecal 
bulk has been confirmed (EFSA 2011u) (Table 9). Several fibres were evaluated for other 
functions, i.e. for their role in maintaining healthy gastro-intestinal function by increasing 
the number of bifidobacteria in the gut. In some cases the studies clearly demonstrated a 
significantly increased number of bifidobacteria in the gut; however, there was no direct 
evidence provided that changes in the number of bifidobacteria in the gut are beneficial for 
gut function (EFSA 2009a). For such claims the beneficial effect needs to be shown. 
6.4 Other food or food constituents 
6.4.1 Antioxidants 
Numerous food constituents possess antioxidant activity, yet, in the health claim evaluation 
process, only a few of them were assessed with a favourable outcome. As in the prebiotics 
case, the claim contains antioxidants is considered a health benefit and should be 
accompanied by a specific health claim. However, apart from vitamins and trace elements 
(Table 7), until now only olive oil polyphenols have been recognised to possess antioxidant 
activity which is beneficial to human health, specifically in the protection of LDL particles 
from oxidative damage (Covas et al. 2006a; Covas et al. 2006b; EFSA 2011v; Marrugat et al. 
2004; Weinbrenner et al. 2004 ). Hydroxytyrosol and its derivatives (e.g. oleuropein complex 
and tyrosol) are the key compounds with such activity, and to bear the claim olive oil it 
should contain enough of them to provide 5mg of these compounds daily. It was noted that 
the concentrations in some olive oils does not allow consumption of such an amount of 
polyphenols in the context of a balanced diet (EFSA 2011v). Many other known antioxidants 
(including flavonoids and flavonols, lycopene, lutein etc.) received unfavourable opinions, 
mostly because of poor characterisation, non-specific health effects or poor evidence for 
such effects. In a recent draft of the Guidance on the scientific requirements for health claims 
related to antioxidants, oxidative damage and cardiovascular health the EFSA noted that it is not 
established that changes in the overall antioxidant capacity of plasma exert a beneficial 
physiological effect in humans. A beneficial physiological effect will therefore need to be 
proven for any specific antioxidant for a successful substantiation.  
6.4.2 Probiotics 
The claim contains probiotics is also considered a health benefit and should be accompanied 
by a specific health claim. However, the EFSA has not released a favourable opinion in 
relation to live organisms other than for live yoghurt cultures in yoghurt, which were shown 
to improve the digestion of lactose in yoghurt in individuals with lactose maldigestion 
(discussed below). The main reasons for the unfavourable opinion were that the 
microorganisms were not properly characterised (in either the health claim application or 
the supporting study of the claimed effect), or that there was poor evidence of the beneficial 
effect. However, many probiotics health claims were returned for re-evaluation and there 
has been a call to provide additional data for scientific evaluation. Discussion about the 
results of the re-evaluation has been very speculative, but it is clear that further research will 
be needed to support a beneficial physiological effect in humans in most (if not all) cases. 
The specific functions will need to be properly addressed.  
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6.4.3 Sport nutrition 
A series of food constituents have been evaluated for sport related general function health 
claims. Caffeine was shown to contribute to increase in endurance performance, reduction 
in the rated perceived exertion during exercise and increased alertness (Table 10). However, 
it is noted that for children consumption of a dose of 5mg/kg body weight could result in 
transient behavioural changes, such as increased arousal, irritability, nervousness or anxiety. 
In relation to pregnancy and lactation, moderation of caffeine intake, from whatever source, 
is advisable (EFSA 2011i). The role of vitamin C in the maintenance of normal function of 
the immune system during and after intense physical exercise was also confirmed, but due 
to the high daily dosage (200mg vitamin C per day in addition to the usual diet) it remains a 
question if such a claim will be authorised. In some EU countries such a dosage of vitamin C 
is considered a medicinal use. Other health claims which received favourable opinions 
include protein and the maintenance of muscle mass, water and the maintenance of normal 
thermoregulation, and creatine and an increase in physical performance during short-term, 
high intensity, or repeated bouts of exercise. The proposed condition for use of these claims 
is presented in Table 10. The role of carbohydrate-electrolyte solutions in the enhancement 
of water absorption during exercise and in the maintenance of endurance performance was 
also evaluated. It was proposed that in order to bear the claim a carbohydrate-electrolyte 
solution should contain 80-350 kcal/L from carbohydrates, and at least 75 % of the energy 
should be derived from carbohydrates which induce a high glycaemic response, such as 
glucose, glucose polymers and sucrose. In addition, these beverages should contain between 
460mg/L and 1150mg/L of sodium, and have an osmolality between 200-330mOsm/kg 
water (EFSA 2011j).  
 
Food or 
ingredient 
Function Conditions of use Reference 
Vitamin C Maintenance of normal 
function of the immune 
system during and after 
intense physical exercise 
200mg vitamin C per day1 
(in addition to the usual diet) 
(EFSA 2009{) 
Protein Maintenance of muscle 
mass 
Source of protein (EFSA 2010|) 
Caffeine Increase in endurance 
performance 
3mg/kg body weight 
(one hour prior to exercise) 
(EFSA 2011h) 
 
Increase in endurance 
capacity 
(EFSA 2011h) 
 
Reduction in the rated 
perceived exertion during 
exercise 
4mg/kg body weight 
(one hour prior to exercise) 
(EFSA 2011h) 
 
Increased alertness 75mg caffeine per serving 
(adults) 
(EFSA 2011i) 
Creatine Increase in physical 
performance during short-
term exercise 
3g per day (EFSA 
2011m) 
Water Maintenance of normal 
thermoregulation 
2.0 L per day (EFSA 2011~) 
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Food or 
ingredient 
Function Conditions of use Reference 
Carbohydrate-
electrolyte 
solutions 
Enhancement of water 
absorption during exercise
Energy: 80-350kcal/L from 
carbohydrates and at least 75 % 
from sugars; Sodium: 460-
1,150mg /L 
Osmolality: 200-330mOsm/kg 
(EFSA 2011j) 
Maintenance of endurance 
performance 
(EFSA 2011j) 
Notes: 1In some countries 200mg of vitamin C daily is considered a medicinal use. 
Table 10. Conditions of use for sport related general function health claims as proposed by 
the EFSA 
6.4.4 Weight management 
For food producers weight-management products are appealing as these can be marketed 
successfully. Weight loss can be interpreted as the achievement of a normal body weight in 
previously overweight subjects. In this context, weight loss in overweight subjects without 
the achievement of a normal body weight is also considered beneficial to health (EFSA 
2010t). However, only a few favourable opinions of the EFSA were published (EFSA 2010o; 
EFSA 2010t; EFSA 2011}). It was established that substituting two daily meals with meal 
replacements helps to lose weight in the context of energy restricted diets. In order to bear 
the claims, a food should contain a maximum of 250 kcal/serving and comply with 
specifications laid in legislation covering foods intended for use in energy-restricted diets 
for weight reduction (EFSA 2010t). Similarly, it was established that replacing the usual diet 
with a very low calorie diet (VLCD) helps to lose weight (EFSA 2011}). VLCDs are diets 
which contain energy levels between 450 and 800 kcal per day, and 100% of the 
recommended daily intakes for vitamins and minerals. They should contain not less than 
50g of high-quality protein, should provide not less than 3g of linoleic acid and not less than 
0.5g alpha-linolenic acid, with a linoleic acid/alpha-linolenic acid ratio between 5 and 15, 
and should provide not less than 50g of available carbohydrates (CODEX STAN 203-19956) 
(EFSA 2011}). VLCDs are typically used for 8-16 weeks. 
6.4.5 Foods for individuals with symptomatic lactose maldigestion 
Lactose maldigestion is a common condition characterised by intestinal lactase deficiency. It 
is most prevalent in Asian, African, Hispanic and Indian populations, but is also common in 
Europe. Most people with primary lactose maldigestion are usually able to tolerate small 
amounts of lactose (EFSA 2009o). Ingested lactose is hydrolysed by an enzyme of the 
microvillus membrane of the enterocytes, called lactase. It is split into the monosaccharides 
glucose and galactose, which are rapidly and completely absorbed within the small 
intestine. In persons with lactose maldigestion, undigested lactose reaches the colon where it 
is degraded to lactic acid, acetic acid, water and carbon dioxide by intestinal bacteria (EFSA 
2011q). In some lactose maldigesters this can elicit symptoms of lactose intolerance, which 
may develop one to three hours after the ingestion of lactose. These symptoms include 
abdominal pain, bloating, flatulence and diarrhoea. It was established that consumption of 
foods with reduced amounts of lactose may help to decrease gastro-intestinal discomfort 
caused by lactose intake in lactose intolerant individuals (EFSA 2011q). However, it was not 
possible to propose a single condition of use because of the great variation in the individual 
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tolerances of lactose intolerant individuals. Additionally, an improvement in lactose 
digestion may be of interest to lactose intolerant subjects (EFSA 2009o). A cause-and-effect 
relationship has been established between the externally administered lactase enzymes and 
breaking down lactose in individuals with symptomatic lactose maldigestion, which can 
alleviate lactose intolerance symptoms. The recommended dose was 4500 FCC (Food 
Chemicals Codex) units with each lactose-containing meal. It was noted that the dose may 
have to be adjusted to individual needs for lactase supplementation and consumption of 
lactose-containing products (EFSA 2009o). Live yoghurt cultures in yoghurt were also 
shown to improve the digestion of lactose in yoghurt in individuals with lactose 
maldigestion (EFSA 2010q). The effect has been confirmed in a number of human studies 
and is based on the ability of specific bacteria to produce active ǃ-galactosidase enzymes in 
the digestive tract. It was proposed that in order to bear the claim, the yoghurt should 
contain at least 108 colony-forming units (CFU) live starter microorganisms (Lactobacillus 
delbrueckii subsp. bulgaricus and Streptococcus thermophilus) per gram (EFSA 2010q). 
6.4.6 Chewing gums 
It was established that there is a cause-and-effect relationship between the consumption of 
sugar-free chewing gum and plaque acid neutralisation, the maintenance of tooth 
mineralisation, and a reduction of oral dryness (EFSA 2009w). The solubility of tooth 
hydroxyapatite crystals drops with the lowering of pH and buffering of acids, and limiting 
the duration of periods of pH drop can prevent demineralisation and promote 
remineralisation of the hydroxyapatite crystals. Acid is produced in plaque through the 
fermentation of carbohydrates by acid-producing bacteria and studies have shown that 
chewing a sugar-free chewing gum enhances saliva flow and counteracts pH drops upon 
sugar-induced acid production. Chewing for at least 20 minutes after meals may be needed 
to obtain the beneficial effect. In the absence of fermentable carbohydrates, no clinically 
relevant reduction on plaque pH may be expected by the consumption of sugar-free 
chewing gum (EFSA 2009w). In a separate opinion it was established that sugar-free 
chewing gum with carbamide contributes to plaque acid neutralisation over and above the 
effect achieved with sugar-free chewing gums without carbamide (EFSA 2011z). At least 
20mg carbamide should be added per piece to communicate such claims.  
6.4.7 Borderline substances 
In some cases the functionality of possible food ingredients enters the borderline between 
food and medicine. A series of such cases has also been revealed in the evaluation of general 
function health claims. The most obvious example is the evaluation of monacolin K from 
rice fermented with the red yeast Monascus purpureus (EFSA 2011t). Red yeast rice is a 
traditional Chinese food product which is still a dietary staple in many Asian countries. 
Depending on the Monascus strains used and the fermentation conditions, it may contain 
Monacolin K, in the form of hydroxy acid and lactone (also known as lovastatin), which 
received a favourable opinion for the maintenance of normal blood LDL-cholesterol 
concentrations (EFSA 2011t). On the EU market there are a number of lovastatin-containing 
medicinal products and it remains controversial if it is possible to set appropriate conditions 
of use that would put this product into a food category. In any case, red yeast rice has not 
been traditionally consumed as a food in Europe and must go through a novel food 
authorisation procedure. However, its use is already possible in some specific food 
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categories (i.e. in food supplements) in some EU countries. Somewhat similar is the case of 
melatonin. While in a number of EU countries this hormone is considered a medicinal 
product, in some countries it is sold as a food supplement. In the health claim evaluation 
process it was confirmed that melatonin helps to reduce the time taken to fall asleep (EFSA 
2011d) and contributes to the alleviation of subjective feelings of jet lag (EFSA 2010u). It is 
proposed that 1mg of melatonin is consumed close to bedtime (EFSA 2011d). 
7. Nutrient profiles 
To exclude the use of nutrition and health claims on foods with overall poor nutritional 
status nutrient profiles should be established, including the exemptions which food or 
certain categories of food must comply with in order to bear the claims (EC 2006). 
Unfortunately, this part of the legislation has not yet been implemented, even though the 
scientific criteria for this were prepared on time (EFSA 2008). The stakeholders have 
obviously been quite effective in lobbying against the setting of nutrient profiles and there is 
little evidence of progress in this area since 2009. Currently, it is not even clear if nutrition 
profiles will be implemented at all (Cappuccio and Pravst 2011). Nevertheless, the 
producers of functional food must be aware that the overall composition of a final product 
should provide health benefits. Particular care should be directed towards those nutrients 
with the greatest public health importance for EU populations, such as saturated fatty acids, 
sodium and sugar, intakes of which generally do not comply with nutrient intake 
recommendations in many Member States (EFSA 2008).  
8. Quality of functional foods 
The quality and safety of functional foods is entirely the responsibility of the producer but 
can be controlled by national authorities. In practice, such controls mainly focus on assuring 
adequate safety by controlling for contaminants and additives (Pravst and Žmitek 2011). 
Nutritional composition is usually not considered a health risk and is therefore less 
controlled. In fact, while labelling requirements have been in existence in many countries for 
more than a decade, analyses of many food constituents are still challenging. The EU 
legislation currently concentrates on regulating the use of vitamins and minerals, while the 
use of other substances with a nutritional or physiological effect is not regulated in detail. 
When discussing the safety and quality control assessment of foods containing particular 
ingredients with biological activity we must distinguish products on the basis of their active 
ingredients; i.e. chemically stable dietary minerals, less stable vitamins, chemical 
compounds other than vitamins and minerals, living microorganisms (i.e. probiotics) etc. 
(Pravst and Žmitek 2011). The appropriate content of these ingredients in final products 
must be achieved using suitable production standards (including quality control of both raw 
materials and the final product) and stability during the manufacturing process and shelf 
life. The low content of an ingredient in a final product is often connected with either 
improper manufacturing (inappropriate purity or insufficient ingredients used in the 
production, uncontrolled manufacturing conditions, and inappropriate formulation) or its 
decomposition during shelf life. In situations where decomposition occurs either during 
manufacturing or shelf life this not only misleads the consumer but might also create 
increased health risks due to the possibility of the uncontrolled formation of by-products. In 
contrast, when not enough ingredients are used during manufacturing the primary concern 
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is about misleading the consumer. In some cases, such scenarios can also pose a risk to 
human health, i.e. in instances of adulteration.  
A significant problem that arises in the evaluation of the quality of functional foods is that 
there are no generally accepted tolerances for the declaration of nutrients and other active 
ingredients in the EU (DG SANCO 2006), although guidelines on this issue have been 
accepted in some countries (Table 11). The task of setting tolerable margins was identified as 
a priority 10 years ago during the discussion that led to the adoption of Directive 
2002/46/EC on food supplements, but this goal has not yet been achieved (Pravst and 
Žmitek 2011). Nevertheless, there is a general agreement that such tolerances should be 
defined at the Community level in order to avoid trade barriers and ensure consumer 
protection (DG SANCO 2006). 
 
 Tolerances for added nutrients 1 
 
Country 
Minerals Water-soluble vitamins Fat-soluble vitamins 
Belgium 90% - 120% 90% - 120% 90% - 120% 
Denmark 80% - 150% 80% - 150% 80% - 150% 
France 80% - 200% 80% - 200%2 80% - 200%2 
Italy 75% - 100% 80% - 130%2 80% - 130%2 
Slovenia 80% - 150% 80% - 150%2 80% - 130% 
Netherlands 80% - 150% 80% - 200% 80% - 200% 
United Kingdom 50% - 200% 50% - 200% 70% - 130% 
Notes: 1 if legislation prescribes minimum and maximum values for the addition of nutrients, the 
analysed amount must not exceed these limits; 2 with exceptions 
Table 11. Tolerance values accepted or practiced in some EU member states (CIAA 2007; DG 
SANCO 2006; IVZ 2009). 
9. Conclusions and future issues 
In the last few years the regulation of nutrition and health claims has been one of the top 
food-related themes discussed in Europe. Regulation covering these areas was indeed 
required. Protecting consumers against misleading claims, along with the harmonisation of 
the European market, were the key issues that needed to be addressed. The regulation 
targets functional foods, a concept which emerged in Japan about 20 years ago to reduce the 
escalating health care costs with a category of foods offering potential health benefits, 
although from a different perspective. At the time, the USA and some EU-member states 
were also at the frontier of developments, but the European Union as a whole was lagging 
far behind. It was decided that the use of pre-approved evidence-based health claims on 
food labels would serve us best and in the ensuing time there has been a focus on creating a 
list of approved claims. In such a system, functional foods are basically defined by the 
limitations and the opportunities for the use of claims. 
Essential nutrients are clearly the winner of the evaluation process. In cases where a well-
established consensus among scientists exists on the biological role of a nutrient, the EFSA 
relied on that consensus and confirmed the cause-and-effect relationship without reviewing 
the primary scientific studies. In most cases, the proposed condition of use is to include at 
least 15% of the RDA of the nutrient per 100g of final product, to enable the use of health 
www.intechopen.com
 
Scientific, Health and Social Aspects of the Food Industry 
 
192 
claims for such a nutrient. This will enable products which are a source of at least one such 
nutrient to communicate health claims, even in cases where there is no deficiency in the 
population. The consumer will recognise such a nutrient as a health added value and there 
are concerns that such claims might flood the market and enable consumers to be legally 
misled. While the authorisation of such health claims may pose a risk of misleading the 
consumer, there are also cases where concerns related to public health arise. Such an 
example is the claim concerning phosphorus and its role in the maintenance of normal 
bones. The intake of phosphorus easily exceeds the recommendations and a bigger intake 
might have adverse effects on bone health (Pravst 2011b). Therefore, both health and ethical 
concerns arise as to whether such claims should be allowed, even though science is not yet 
clear on this issue. A useful solution in such cases would be to authorise claims with more 
specific conditions of use. 
Foods promoted with claims may be perceived by consumers as having a health advantage 
over other foods and this may encourage consumers to make choices which directly 
influence their total intake of individual nutrients in a way which would run counter to 
scientific advice. The regulation aims to avoid a situation where claims mask the overall 
nutritional status of a food product and confuse consumers when trying to make healthy 
choices in the context of a balanced diet with the introduction of nutrient profiles. However, 
these profiles have not yet been established and it is not even clear if they will be 
implemented at all. In a situation in which food producers have the power to stimulate the 
consumption of foods with a poor nutritional status we must count on their commitment to 
serving consumers (Pravst 2011a).  
All of the above issues suggest that we are still far from the target. The scientific 
substantiation of health claims for non-essential ingredients is very important and 
substantial additional research will be needed to get new claims approved. A detailed 
examination of all the concerns raised by the EFSA in its published opinions, together with 
some additional advice about expectations related to the scientific substantiation of health 
claims, should result in the improved quality of clinical testing for bioactive components 
and functional foods. 
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